These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16495801)

  • 1. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil.
    Brunet M; Cirera I; Martorell J; Vidal E; Millán O; Jiménez O; Rojo I; Londoño MC; Rimola A
    Transplantation; 2006 Feb; 81(4):541-6. PubMed ID: 16495801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients.
    Minmin S; Zhidong G; Hao C; Weixia Z; Baiyong S; Bing C; Chuan S; Xiaxing D; Xi Z
    J Clin Pharmacol; 2010 Dec; 50(12):1388-96. PubMed ID: 20220042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
    Kamar N; Marquet P; Gandia P; Muscari F; Lavayssière L; Esposito L; Guitard J; Canivet C; Peron JM; Alric L; Suc B; Saint-Marcoux F; Rostaing L
    Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical assessment of mycophenolate drug monitoring after liver transplantation.
    Hwang S; Lee SG; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Choi NK; Kim KW; Yu YD; Park GC; Park PJ; Choi YI
    Clin Transplant; 2010; 24(2):E35-42. PubMed ID: 20070319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
    Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G; Foster J; Berard R; Mai I; Lepage N
    Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.
    Parant F; Rivet C; Boulieu R; Gagnieu MC; Dumortier J; Boillot O; Lachaux A
    Ther Drug Monit; 2009 Dec; 31(6):727-33. PubMed ID: 19881404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
    Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
    Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
    Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.